Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Buy

Wall Street Data Solutions Rating

Sell

C

ANI Pharmaceuticals, Inc. (ANIP)

Pharmaceutical Preparations

https://www.anipharmaceuticals.com

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

210 MAIN STREET WEST
BAUDETTE, MN

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/13/1999

Market Cap

1,258,020,582

Shares Outstanding

20,430,000

Weighted SO

20,426,683

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

EGRX --.--%

PAHC --.--%

DCPH --.--%

PBH --.--%

ALKS --.--%

RDY --.--%

COLL --.--%

PCRX --.--%

PROC --.--%

Beta

0.7580

Last Div

0.0000

Range

48.2-70.81

Chg

-1.2800

Avg Vol

243037

Mkt Cap

1258020582

Exch

NASDAQ

Country

US

Phone

218 634 3500

DCF Diff

121.7823

DCF

-60.6823

Div Yield

0.0000

P/S

2.3342

EV Multiple

12.7165

P/FV

2.5359

Div Yield %

0.0000

P/E

42.7830

PEG

1.6320

Payout

0.0602

Current Ratio

3.9661

Quick Ratio

3.0699

Cash Ratio

1.7153

DSO

112.4833

DIO

181.0159

Op Cycle

293.4992

DPO

70.2445

CCC

223.2547

Gross Margin

0.5307

Op Margin

0.0877

Pretax Margin

0.0659

Net Margin

0.0501

Eff Tax Rate

0.2391

ROA

0.0293

ROE

0.0602

ROCE

0.0605

NI/EBT

0.7609

EBT/EBIT

0.7516

EBIT/Rev

0.0877

Debt Ratio

0.3368

D/E

0.6804

LT Debt/Cap

0.4042

Total Debt/Cap

0.4049

Int Coverage

3.9595

CF/Debt

0.3631

Equity Multi

2.0203

Rec Turnover

3.2449

Pay Turnover

5.1961

Inv Turnover

2.0164

FA Turnover

10.4367

Asset Turnover

0.5853

OCF/Share

5.8274

FCF/Share

4.8771

Cash/Share

12.7868

OCF/Sales

0.2089

FCF/OCF

0.8369

CF Coverage

0.3631

ST Coverage

132.4612

CapEx Coverage

6.1318

Div&CapEx Cov

5.6333

P/BV

2.5359

P/B

2.5359

P/S

2.3342

P/E

42.7830

P/FCF

13.3505

P/OCF

10.2652

P/CF

10.2652

PEG

1.6320

P/S

2.3342

EV Multiple

12.7165

P/FV

2.5359

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 12, 22:30 ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ GlobeNewswire Inc. Aug 08, 01:44 ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering GlobeNewswire Inc. Jan 23, 06:50 ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP Zacks Investment Research Jan 19, 18:15 ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note Zacks Investment Research Jan 19, 18:15 ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note Zacks Investment Research Jan 19, 18:15 ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note Zacks Investment Research Jan 19, 18:15 ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note GlobeNewswire Inc. Jan 16, 06:50 ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP GlobeNewswire Inc. Nov 22, 09:26 ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference GlobeNewswire Inc. Nov 08, 06:50 ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance GlobeNewswire Inc. Oct 30, 06:50 ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences GlobeNewswire Inc. Oct 25, 06:50 ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

Revenue Product Segmentation